sotorasib
amgen
['lumakras', 'amgen']
confirmatory trial data at #esmo22 raise some first doubts that 's lumakras will gain full approval this year, even though it met the primary endpoint 
The leading voice for decision-makers throughout the global biopharma ecosystem. 
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6